Epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase involved in the etiology of several human cancers. Cetuximab is an EGFR-blocking antibody that has been approved for the treatment of patients with head and neck squamous cell carcinoma and metastatic colorectal cancer. Previous reports have shown that EGFR translocation to the nucleus is associated with cell proliferation. Here we investigated mechanisms of acquired resistance to cetuximab using a model derived from the non-small cell lung cancer line H226. We demonstrated that cetuximabresistant cells overexpress HER family ligands including epidermal growth factor (EGF), amphiregulin, heparinbinding EGF and b-cellulin. Overexpression of these ligands is associated with the nuclear translocation of the EGFR and this process was mediated by the Src family kinases (SFK). Treatment of cetuximab-resistant cells with the SFK inhibitor, dasatinib, resulted in loss of nuclear EGFR, increased membrane expression of the EGFR and resensitization to cetuximab. In addition, expression of a nuclear localization sequence-tagged EGFR in cetuximab-sensitive cells increased resistance to cetuximab both in vitro and in mouse xenografts. Collectively, these data suggest that nuclear expression of EGFR may be an important molecular determinant of resistance to cetuximab therapy and provides a rationale for investigating nuclear EGFR as a biomarker for cetuximab response. Further, these data suggest a rationale for the design of clinical trials that examine the value of treating patients with cetuximab-resistant tumors with inhibitors of SFKs in combination with cetuximab.
Introduction
The epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase that is important in oncogenesis. Ligand activation of the EGFR leads to downstream signaling of several prosurvival cascades, such as the RAS/RAF/MEK/ ERK/MAPK and PI3K/Akt pathways. Activation of the EGFR ultimately promotes cell proliferation, angiogenesis, invasion, metastasis and survival making it one of the most promising molecular targets in cancer therapy (Yarden and Sliwkowski, 2001; Gupta et al., 2002; Arteaga, 2003; Viloria-Petit and Kerbel, 2004; Bianco et al., 2005; Camp et al., 2005; Kobayashi et al., 2005; Pao et al., 2005) .
EGFR has been an actively investigated target over the last decade with five FDA agents approved in oncology since 2003. Two distinct molecular approaches to EGFR inhibition have emerged: (1) monoclonal antibodies directed against the ligand-binding site of the EGFR and (2) tyrosine kinase inhibitors directed against the intracellular tyrosine kinase domain. Although both strategies of inhibition have demonstrated promising antitumor activity in patients with metastatic colorectal cancer, non-small cell lung cancer (NSCLC), breast cancer and head and neck squamous cell carcinoma (HNSCC), only B10-20% of patients manifest major clinical responses. Response to these agents appears to be limited by intrinsic as well as acquired resistance (Gupta et al., 2002; Arteaga, 2003; Viloria-Petit and Kerbel, 2004; Bianco et al., 2005; Camp et al., 2005; Kobayashi et al., 2005; Pao et al., 2005) . Several mechanisms of resistance to cetuximab have emerged including deregulated ubiquitination, amplified HER3 signals, increased transforming growth factor-a, and altered angiogenesis (Viloria-Petit et al., 2001; Lu et al., 2007; Rajput et al., 2007; Wheeler et al., 2008) . Although each of these studies suggests rational mechanisms of intrinsic and/or acquired resistance, our detailed knowledge of EGFR inhibitor resistance remains relatively ill defined (Mukohara et al., 2005) .
It has been reported that EGFR family members can be shuttled from the plasma membrane to the nucleus (Xie and Hung, 1994; Lin et al., 2001; Ni et al., 2001; Offterdinger et al., 2002; Wang et al., 2004 Wang et al., , 2006 Giri et al., 2005; Lo et al., 2005a Lo et al., , 2006b Lo and Hung, 2006; Massie and Mills, 2006; Liao and Carpenter, 2007) . Nuclear EGFR (nEGFR) has been demonstrated in highly proliferative tissues and linked with poor clinical outcome in breast, oropharyngeal squamous cell carcinoma (SCC), and ovarian cancer (Psyrri et al., 2005; Lo and Hung, 2006; Xia et al., 2009) . Nuclear EGFR has two identified functions in the nucleus: (1) as a transcription factor and (2) in the direct phosphorylation of proliferating cell nuclear antigen (PCNA). As a transcription factor, EGFR has been shown to interact with STAT3 and E2F1 to mediate transcription of cyclin D1, iNOS, B-Myb and Aurora kinase A (Marti et al., 1991; Cao et al., 1995; Lin et al., 2001; Lo et al., 2005a Lo et al., , 2006b Hanada et al., 2006; Lo and Hung, 2006; Hung et al., 2008) . In addition to transcription-regulated events, the EGFR has been shown to phosphorylate PCNA on tyrosine 211, thus stabilizing chromatinbound PCNA. This phosphorylation event correlates with pronounced cell proliferation (Wang et al., 2006) .
In this study, we investigated the role of nEGFR in the resistance to cetuximab therapy. We showed that cells with acquired resistance to cetuximab have increased Src family kinase (SFK) activity, and this is linked to the translocation of the EGFR to the nucleus. Collectively, our findings reported herein suggest that nuclear expression of EGFR may be a critical determinant for resistance to cetuximab therapy and provides a rationale for designing clinical trials to examine the value of treating patients with resistance to cetuximab with inhibitors of SFKs in combination with cetuximab.
Results

Cetuximab-resistant cells have increased nuclear EGFR expression
We have previously described the development and characterization of NCI-H226 NSCLC lines with acquired resistance to cetuximab (Wheeler et al., 2008) . The development of this model resulted in six stable cetuximab-resistant clones for the H226 NSCLC line: HC1, HC4, HC5, HC6, HC7 and HC8. The sensitive parental line was designated HP. Three of these clones (HC1, HC4 and HC8) were tested for their sensitivity to cetuximab relative to the parental controls ( Figure 1a ). All clones displayed a robust cetuximabresistant phenotype when challenged with 100 nM of cetuximab as compared to parental controls.
Nuclear expression of EGFR has been inversely correlated with survival in breast, oropharyngeal and ovarian cancers (Psyrri et al., 2005; Lo et al., 2005b) . Based on these published results, we investigated nEGFR expression in cetuximab-resistant cells relative to the parental controls to determine if nEGFR can function as a mechanism of escape to cetuximab therapy. We analysed the cytoplasmic and nuclear distribution of EGFR in cetuximab-resistant cells. Figure 1b shows that all three cetuximab-resistant clones had a dramatic increase in nuclear expression of the EGFR relative to the parental controls. We next utilized confocal microscopy to confirm nEGFR localization in cetuximab-resistant clones. These findings showed robust EGFR expression in all three clones in the nucleus, perinuclear membranes and cytosol ( Figure 1c) . Quantification of the cytoplasmic and nuclear fractions of each cetuximab-resistant clone, relative to parental controls, is represented in Figure 1d and indicated a B1.5-fold increase in cytosolic expression and a B2-2.5-fold increase in nuclear expression.
Nuclear EGFR has been shown to be associated with the transcription of cell cycle genes (cyclin D1, B-myb and Aurora kinase A), DNA repair and DNA synthesis activity (PCNA phosphorylation and stability; Bandyopadhyay et al., 1998; Lin et al., 2001; Dittmann et al., 2005; Lo et al., 2005a Lo et al., , 2006b Friedmann et al., 2006; Wang et al., 2006; Hung et al., 2008) . To confirm that the nEGFR observed in the cetuximab-resistant clones had nuclear function, we investigated the level of expression of these proteins in cetuximab-resistant clones relative to the parental controls. These experiments revealed that Cyclin D1, B-myb and PCNA were increased in their expressions (Figure 1e ). Collectively, these data indicate that cells with acquired resistance to cetuximab have increased expressions of nEGFR, Cyclin D1, B-myb and PCNA.
Nuclear EGFR in cetuximab-resistant cells is driven by EGFR ligands
It has been clearly demonstrated that EGF stimulates translocation of the EGFR to the nucleus (Hsu and Hung, 2007) . We therefore, hypothesized that cetuximab-resistant cells may have increased expression of EGFR ligands leading to chronic EGFR translocation to the nucleus. We performed DNA microarray analysis comparing HP parental cells versus the HC4 cetuximabresistant clone. Upregulation of several HER family ligands including EGF (B20-fold), heparin-binding EGF (HB-EGF; B12-fold), amphiregulin (AR; B20-fold) and b-cellulin (B3-fold) were identified in this microarray analysis (data not shown). To extend these findings to all resistant clones we performed real-time quantitative PCR to validate EGF, HB-EGF, AR and b-cellulin gene expressions in passage-controlled cetuximab-resistant clones HC1, HC4 and HC8 relative to parental control (Figure 2a ). Figures 2a-d represent several functional assays to confirm the importance of EGFR ligands in the translocation of EGFR to the nucleus. To determine which of these ligands had the potential to drive the EGFR into the nucleus, we treated HP parental cells (low nEGFR expression) with purified ligands (200 ng/ml) and measured nEGFR. Each ligand (EGF, HB-EGF, AR, b-cellulin) induced nuclear translocation of the EGFR to varying degrees in HP parental cells (Figure 2a) .
We expanded on these findings to determine if conditioned media from the cetuximab-resistant clones (HC1, HC4 and HC8) could induce nuclear translocation of the EGFR in HP parental cells (low nEGFR expression). Conditioned media from HP, HC1, HC4 and HC8 were collected after 72 h and were incubated with HP cells that have been serum starved for 24 h. Nuclear proteins were isolated 1 h after the addition of the conditioned media and fractionated by SDS-polyacrylamide gel electrophoresis (PAGE). These results showed that conditioned media from the cetuximab-resistant clones, but not from the HP parental cells, could induce EGFR translocation to the nucleus (Figure 2b ). EGFR ligands are released from the cytoplasmic membrane via activation of tumor necrosis factor-a converting enzyme (TACE; Sunnarborg et al., 2002; Borrell-Page`s et al., 2003) . We used the TACE inhibitor, TAPI2, to block the release of EGFR ligands in cetuximab-resistant cells as well as the parental control and measured the effect on nuclear translocation of the EGFR (Figure 2b ). The results of these experiments indicated an approximate 3-to 5-fold decrease in nEGFR expression in cetuximab-resistant clones in the TAPI2 treated groups. These data suggest that blockade of TACE and thus release of growth factors results in decreased nuclear translocation of the EGFR.
In Figure 2c , HP, HC1, HC4 and HC8 were serum starved for 3, 6, 12 and 24 h and nEGFR translocation was then assessed. All cetuximab-resistant clones (HC1, HC4 and HC8), but not the parental HP, had increased nuclear translocation of the EGFR as time increased. These results suggest that factors from the cetuximab- (e) Relative amounts of cyclin D1, B-myb and proliferating cell nuclear antigen (PCNA) in cetuximab-resistant clones (HC1, HC4, HC8) were quantified by ImageJ software and normalized against the parental, cetuximab-sensitive line (HP). Histone H3 was used as a loading and nuclear fraction purity control.
Nuclear EGFR and resistance to cetuximab C Li et al resistant cells are released and lead to nuclear translocation of the EGFR over time.
If cetuximab-resistant cells have increased EGFR ligands and these ligands appear to drive nEGFR, we investigated whether this process would result in resistance to cetuximab. Growth proliferation assays indicated that the addition of ligand results in robust resistance to cetuximab (Figure 2d ). Interestingly, HB-EGF and b-cellulin, which induced the most pronounced nEGFR translocation, resulted in the largest increase in resistance to cetuximab (Figures 2a and d ).
Src family kinases mediate ligand-induced EGFR translocation to the nucleus
We have previously shown that cells with acquired resistance to cetuximab have increased SFK activity relative to parental control (Wheeler et al., 2009 ). We hypothesized that ligand-induced EGFR translocation to the nucleus may be mediated by SFK. Pretreatment of the HP parental cells with the SFK inhibitor, dasatinib for 24 h before ligand stimulation completely blocked EGFR translocation to the nucleus by these ligands ( Figure 3a) . As cetuximab-resistant cells have increased expression of EGFR ligands, SFK activity and nEGFR, we designed experiments to determine if these were linked. We investigated whether SFK blockade using dasatinib could reduce nEGFR expression in the cetuximabresistant clones HC1, HC4 and HC8. Cetuximabresistant clones were treated with vehicle or dasatinib for 24 h; the cells were then fractionated for the cytoplasmic EGFR (cEGFR) or nEGFR. Dasatinib treatments lead to a 2.7-to 5.5-fold decrease in nEGFR expression in the cetuximab-resistant clones (Figure 3b ). The results of this experiment indicated that cetuximabresistant cells have increased the release of EGFR ligands, which then induce the translocation of the EGFR to the nucleus and this process is dependent on SFK.
It has been well characterized that membrane-bound EGFR translocates from the membrane to the nucleus (Lin et al., 2001; Lo et al., 2006a; Hsu and Hung, 2007) . We postulated that SFK blockade inhibited this process and would result with higher membrane levels in cetuximab-resistant clones after dasatinib treatment. To test this hypothesis, we treated HP, HC1, HC4 and HC8 with 50 nM dasatinib for 24 h and performed flow cytometric analysis on membrane EGFR expression ( Figure 3c ). HP showed a decrease in membrane EGFR levels whereas all three cetuximab-resistant clones showed an increase in membrane expression of the EGFR after dasatinib treatment.
With an increase in EGFR membrane expression and a decrease in nuclear expression after dasatinib treatment, we asked the question of whether cetuximabresistant clones would be more sensitive to cetuximab therapy. We performed proliferation analysis assays using dimethyl sulfoxide (DMSO) control, 100 nM cetuximab, 25 nM dasatinib or their combination on HP, HC1, HC4 and HC8. The results of these experiments showed that dasatinib induced mild growth inhibition on cetuximab-resistant cells but the combination of the two drugs showed augmentation of growth inhibition ( Figure 3d ). These results suggest that blockade of SFK can block nuclear translocation of the EGFR, increase membrane EGFR and thus make cells more sensitive to cetuximab therapy.
Nuclear localization sequence-tagged EGFR leads to increased resistance to cetuximab To isolate the effects of nEGFR from ligand-induced nuclear translocation of EGFR, we designed a retrovirus expressing wild-type human EGFR fused to a nuclear localization sequence (NLS) tag, followed by a myc tag for identification of the transgene (EGFR-NLS/ Myc, Figure 4a ). We infected cetuximab-sensitive parental line, HP, with EGFR-NLS/Myc or vector only. From these experiments we obtained three EGFR-NLS/Myc-expressing clones designated C Figure 4a shows the characterization of these three clones. The nuclear fractions were purified and immunoprecipitated with a myc antibody. All clones were positive for the myc tag, EGFR and phospho-tyrosine (p-Tyr) of the EGFR, indicating active EGFR by western blot analysis. These results were followed by immunofluorescence analysis of EGFR expression in the vector only and three EGFR-NLS/Myc-expressing clones. Each EGFR-NLS/Mycexpressing clone had robust EGFR expression in the nucleus and perinuclear membrane as well as cytosolic expression. These results indicated that our transgene was expressed in the nuclear fraction and active as demonstrated by total phosphorylation of tyrosine residues on the EGFR.
It has been reported that EGFR activates expression of cyclin D1 and B-myb (Lin, 2001; Hanada, 2006) . To determine if the NLS-tagged EGFR had nuclear function, we measured the levels of cyclin D1 and Bmyb. Figure 4b indicates that all EGFR-NLS/Mycexpressing clones have a 1.9-to 2.3-fold increase in expression of B-myb and a 1.4-to 1.6-fold increase in cyclin D1 expression. We utilized these clones with increased nEGFR expression and tested the hypothesis were treated with 200 ng/ml of each HER family ligand for 1 h after 24 h of serum starvation. Cells were harvested and the nuclear protein was fractionated by SDS-polyacrylamide gel electrophoresis (PAGE) followed by immunoblotting for indicated proteins. Histone H3 was used as a loading control. Expression of nuclear EGFR (nEGFR) after treatment with each ligand was quantitated using ImageJ software and normalized against untreated cells. (b) Conditioned media from cetuximab-resistant cells can lead to increased nuclear translocation of the EGFR. Conditioned media from cetuximab-resistant clones (HC1, HC4, HC8) or parental cells (HP) was placed on HP cells and incubated for 1 h; cetuximab-resistant cells and parental control were treated with 100 mM TAPI2 for 24 h. Cells were harvested and nuclear protein fractionated on SDS-PAGE followed by immunoblotting for EGFR. Histone H3 was used as a loading control. Expression of nEGFR was quantitated using ImageJ software; the untreated cells were compared to TAPI2 treated cells. (c) Serum starvation leads to increased nEGFR in cetuximab-resistant clones, but not parental cell lines. Cetuximab-resistant cells and parental control were placed in serum-free medium and cells were harvested at 3, 6, 12 and 24 h. Nuclear protein was fractionated by SDS-PAGE, followed by immunoblotting for anti-EGFR antibody. Histone H3 was used as loading control. Nuclear EGFR and resistance to cetuximab C Li et al that this would result in increased resistance to cetuximab therapy. In Figure 4c , we report that relative to the parental HP controls each clone exhibited an approximately 50% increase in resistance to cetuximab treatment. Collectively, these data suggest that nuclear expression of the EGFR contributes to resistance to cetuximab therapy.
To examine whether these clones with nEGFR expression would be cetuximab-resistant in vivo, we inoculated athymic nude mice with HP cetuximabsensitive parental cells ( ) were treated with 100 nM of cetuximab and growth was measured using the growth proliferation assay and plotted as growth relative to untreated control. Data points are represented as mean±s.e.m. (n ¼ 3). *Po0.05.
Nuclear EGFR and resistance to cetuximab C Li et al or 0.1 mg of cetuximab twice per week. The results of this experiment indicate two major findings. First, tumor cells that express nEGFR grew approximately twice as fast relative to the HP or V 0 controls. This is noted in Figure 5 . It took the HP and V 0 cells approximately 27 days to reach 100 mm 3 , whereas all three EGFR-NLS/Myc-expressing clones reached the same tumor volume at approximately 12-13 days. This work was confirmed on a repeat experiment. Secondly, the three EGFR-NLS/Myc-expressing clones showed no statistical difference in growth to the IgG controls in response to cetuximab. Taken together, these results suggest that expression of an NLS-tagged EGFR can contribute to resistance to cetuximab in vivo.
Cells that have nuclear EGFR are intrinsically resistant to cetuximab H226 lines represent a NSCLC model of acquired resistance to cetuximab. However, intrinsic resistance to EGFR-targeted therapy is a significant clinical problem. We were interested to determine if other tumor cell lines with known responses to cetuximab in vitro could be correlated with nEGFR expression. To test this hypothesis, we utilized nine established HNSCC lines: SCC1, SCC4Y, SCC6, SCC11A, SCC14A, SCC17B, SCC22B, SCC37A and SCC1483. Cytoplasmic and nuclear protein from these cell lines were fractionated and blotted for EGFR (Figure 6a ). Cells were treated with vehicle or 5 nM of cetuximab for 72 h and MTT assays performed (Figure 6b ). The results of this experiment indicated that cells that have intrinsic resistance to cetuximab therapy, in vitro, have increased nEGFR (SCC4Y, SCC6, SCC11A and SCC14A) and those with low nEGFR have a higher sensitivity to cetuximab treatment (SCC1, SCC17B, SCC37A and SCC1483). SCC22B was used as an EGFR negative expressing line, and thus was not responsive to cetuximab therapy.
Discussion
Cetuximab has shown great promise in clinical oncology, but is limited by intrinsic as well as acquired resistance. These resistance issues present a clinical obstacle for the optimal advancement of this promising molecular targeting agent. In this study we investigated mechanisms of acquired resistance to cetuximab using previously established cetuximab-resistant tumor clones following long-term exposure to cetuximab (Wheeler et al., 2008) . Subcellular analysis of EGFR localization in cetuximab-resistant clones indicated a marked increase in nuclear expression of the EGFR (Figures Nuclear EGFR and resistance to cetuximab C Li et al 1b-d). Emerging evidence over the last decade has indicated that nEGFR has been detected in highly proliferative tissues and linked with poor clinical outcome in breast cancer, oropharyngeal SCC and ovarian cancer (Psyrri et al., 2005; Lo and Hung, 2006; Xia et al., 2009) . Furthermore, nEGFR functions as a transcription factor for cyclin D1, iNOS, B-myb and Aurora kinase A (Marti et al., 1991; Cao et al., 1995; Lin et al., 2001; Lo et al., 2005a Lo et al., , 2006b Hanada et al., 2006; Lo and Hung, 2006; Hung et al., 2008) , as well as phosphorylates and stabilizes PCNA (Wang et al., 2006) . These data suggest that nEGFR provides a 'second compartment' of proliferation mediated by the EGFR, the first compartment being the classical membrane-bound EGFR signaling through the RAS/ RAF/MEK/MAPK pathway. Analysis of cetuximabresistant clones indicated a marked upregulation of cyclin D1, B-myb and PCNA demonstrating that nEGFR was functional in cetuximab-resistant clones. Together, these observations suggest a potential model of resistance to cetuximab therapy (Figure 7) . It has been reported that EGF stimulation can induce the accumulation of EGFR in the nucleus (Hsu and Hung, 2007) . This finding led us to investigate the levels of ligand expression in cetuximab-resistant cells (Figure 2a) . In addition to EGF, we found several EGFR ligands to be increased. Furthermore, we found that all ligands that were upregulated had the potential to induce translocation of the EGFR to the nucleus with varying degrees (Figure 2a ). These data suggest that deregulation of EGFR ligands have the potential to drive EGFR to the nucleus. Furthermore, blockade of TACE, the enzyme necessary for release of EGFR ligands from the membrane (Sunnarborg et al., 2002; Borrell-Page`s et al., 2003) , dramatically decreased nEGFR in all cetuximab-resistant clones, further strengthening a role for ligands in this process (Figure 2b) . If EGFR ligands can drive nEGFR, then ligand alone should induce moderate levels of resistance to cetuximab. In Figure 2d , we tested this hypothesis by adding individual ligands or ligand plus cetuximab and measured the resistance. Each ligand resulted in a varying degree of resistance but appeared that HB-EGF and b-cellulin, which induced more accumulation of EGFR in the nucleus (Figure 2a) , correlated with the most robust resistance (Figure 2d ). Taken together, these findings indicate that EGFR ligands may be a critical determinant of inducing resistance to cetuximab and may be a viable screening tool for therapeutic response to cetuximab. Similar findings have been reported for additional HER family ligands in the resistance to HER family inhibitor therapy (Rajput et al., 2007; Ritter et al., 2007) . Collectively our results and these reports suggest that surveillance of HER family ligands levels may provide an indicator of therapeutic response to cetuximab and other HER family inhibitors.
Recent experiments have shown that EGF can induce nuclear translocation of the EGFR. In Figure 3a , we expanded on this finding and showed that EGF, HB-EGF, AR and b-cellulin drive EGFR to the nucleus. Furthermore, we showed that dasatinib could block this translocation. These findings suggest that EGFR movement to the nucleus is dependent, in part, on SFK, and this may be an early signal in the translocation. Dasatinib treatment of cetuximab-resistant clones led to a dramatic decrease in the nEGFR (Figure 3b ). Taken together, these findings suggest that overexpression of EGFR ligands initiate movement of the EGFR to the nucleus, mediated by SFK. Blockade of SFK may represent a unique therapeutic target to block nEGFR in patients.
Our results also imply that blockade of SFK led to increased EGFR on the plasma membrane and not the nucleus (Figure 3c ). This is most likely due to the fact that SFKs are an initial signal for movement of the EGFR from the membrane to the nucleus. We postulated that increased membrane EGFR and loss of the 'second compartment' of EGFR signaling in the nucleus after SFK blockade may restore sensitivity to cetuximab. This was seen in Figure 3d where the combinatorial therapy of dasatinib and cetuximab had greater impact than either agent alone. The overall findings from this series of experimentations indicate that targeting both the EGFR and SFK may provide a valuable clinical strategy to explore. Investigations into which Src family member may regulate EGFR translocation to the nucleus remain to be elucidated. 
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It is difficult to determine if nEGFR itself can drive resistance because the presence of ligand appears to be necessary. We took steps to distinguish these two processes by overexpressing EGFR tagged to an NLS (EGFR-NLS) in the cetuximab-sensitive HP parental lines in vitro and in vivo (Figures 4 and 5) . Three different EGFR-NLS/Myc-expressing clones were localized to the nucleus, were tyrosine phosphorylated and resulted in the upregulation of Cyclin D1 and B-myb (Figures 4a and b) . Each EGFR-NLS/Myc-expressing clone had increase in resistance to cetuximab in vitro (Figure 4c ). In addition, when these tumor cells were utilized in mouse xenograft models and challenged repeatedly with cetuximab, all three clones showed no significant difference in growth relative to the IgG control, whereas the HP and the vector only controls had statistically significant tumor growth control with cetuximab ( Figure 5 ). Collectively these data support the hypothesis that nEGFR, in part, can play a role in resistance to cetuximab therapy.
Nuclear EGFR has been strongly correlated with poor overall survival in several tumor types (Lo et al., 2005b; Psyrri et al., 2008; Xia et al., 2009) . In summary, this is the first report indicating that nEGFR may play a functional role in the response to molecular therapeutics agents. The findings reported herein have clinical implications for the design of optimal therapeutic strategies. In this model, we demonstrate that HER family ligands are upregulated in the cells with acquired resistance to cetuximab. This in turn enhances the translocation of the EGFR to the nucleus. This process appears to be dependent on SFK. Once in the nucleus, EGFR performs several functions that mediate proliferation of tumor cells. In patients where this mechanism may be prominent, SFK inhibitor, dasatinib, represents an approach inhibiting nuclear translocation, leading to removal of nEGFR and its functions with resensitization to cetuximab therapy. Furthermore, these findings suggest that nEGFR may prove a viable molecular target. This may be undertaken by targeting nEGFRexpressing tumors with EGFR tyrosine kinase inhibitor (erlotinib and gefitinib) as they can diffuse across the membrane and abrogate nEGFR kinase function such as phosphorylation of PCNA. Nuclear EGFR and resistance to cetuximab C Li et al lines have already been suggested (Wheeler et al., 2008) . In addition, targeting with dasatinib and cetuximab either concomitantly or sequentially may be a viable clinical approach for individuals with nuclear expression of EGFR.
Materials and methods
Cell culture
The human NSCLC line NCI-H226 was purchased from ATCC (Manassas, VA, USA) and maintained in 10% fetal bovine serum (FBS) in RPMI1640 (Mediatech Inc., Manassas, VA, USA) with 1% penicillin and streptomycin. The development of cells with acquired resistance has been previously described (Wheeler et al., 2008 
Plasmid constructs and transfection
Wild-type human EGFR cDNA was subcloned into the NcoI/ NotI restriction sites of the pCMV/myc/nuc vector to create the EGFR-NLS/myc construct (Invitrogen). This was then amplified via the polymerase chain reaction and subcloned into the pQCXIP retroviral vector (Clontech, Mountain View, CA, USA). Virus was generated according to the manufacturer's recommendations. Infected cells were grown in RPMI1640 medium containing puromycin (2 mg/ml). Stable clones were selected and maintained in RPMI1640 with 0.5 mg/ml of puromycin.
Cell proliferation assay
Exponentially grown cells were seeded in six-well plates. Following treatment, monolayers were washed with phosphate-buffered saline (PBS) and fixed/stained with 0.5% crystal violet. Plates were air dried overnight and dye was eluted with 0.1 M sodium citrate (pH 4.2) in ethanol (1:1). Elution was transferred to 96-well plates, and the absorbance was read at 540 nm to determine cell growth. The percentage cell growth was calculated by comparison of the A540 reading from treated versus control cells. The antiproliferative effect of cetuximab ( Figure 6b ) was evaluated using MTT assay (Wheeler et al., 2009) .
Cellular fractionation and immunoblotting analysis
Whole cell protein lysate was obtained with lysis buffer (Wheeler et al., 2008) . Cellular fractionation was performed as described previously (Hsu and Hung, 2007) . Protein was quantitated using the Bradford method (Bio-Rad Laboratories, Hercules, CA, USA). Western blotting was performed as described previously (Wheeler et al., 2008) . The NIH ImageJ program was used to measure densitometry of the western bands. The antibodies used in this study were as follows: EGFR, p-EGFR (Tyr1173), CyclinD1, B-Myb, horseradish peroxidase-conjugated goat-anti-rabbit IgG and goat-anti-mouse IgG were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). PCNA, poly (ADP-ribose)-polymerase (PARP) and histone H3 were obtained from Cell Signaling Technology (Beverly, MA, USA). Phospho-tyrosine (4G10) was purchased from Millipore (Billerica, MA, USA), a-tubulin from Calbiochem (San Diego, CA, USA),and c-Myc from Invitrogen.
Immunoprecipitation
Nuclear lysates containing 0.2 mg of protein were incubated overnight with 2 mg of anti-Myc antibody. After adding 30 ml of protein A/G agarose beads, nuclear lysates were incubated for another 2 h at 4 1C. The immunoprecipitates were pelleted by centrifugation and washed three times with lysis buffer and three times with PBS. The captured immunocomplexes were then eluted by boiling the beads in 2 Â SDS sample buffer for 5 min and subjected to immunoblot analysis.
Flow cytometric analysis
Cells were washed in PBS and harvested with trypsin-EDTA (0.05% solution; Gibco, Carlsbad, CA, USA). A cell suspension containing 1 Â 10 6 cells in 100 ml staining buffer (SB-PBS containing 1% bovine serum albumin (BSA)) was incubated with 2 mg of either control IgG or anti-EGFR fluorescein isothiocyanate (FITC)-conjugated antibodies (Santa Cruz Biotechnology Inc.) for 1 h at 4 1C. Cells were washed and resuspended in 300 ml of SB. Propidium iodide (PI), at final concentration of 5 mg/ml, was added to each sample just before analysis on the cytometer. Samples were analysed on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) and a minimum of 20 000 events per sample was acquired. Histogram analysis was performed with FlowJo software (Tree Star Inc., Ashland, OR, USA). Data were restricted to live events based on PI exclusion.
Immunofluorescence assay
Approximately 2 Â 10 3 cells were seeded on a four-well glass chamber slide (Nalgene Nunc, Naperville, IL, USA). Fortyeight hours later, cells were washed 3 times with PBS and fixed with 2% formaldehyde for 15 min at room temperature. Cells were incubated in ice-cold 100% methanol for 10 min at À20 1C and blocked with 5% normal serum in PBS with 0.3% Triton X100 solution for 1 h at room temperature and incubated with anti-EGFR antibody overnight at 4 1C. Next, cells were incubated with FITC-conjugated appropriate secondary antibody in PBS containing 0.3% Triton X100 and 1% BSA for 2 h. Slides were mounted using ProLong gold with DAPI (Invitrogen). Fluorescence microscopy, photography and measurement intensity were carried out using BD Pathway 855 (BD Biosciences).
Real-time quantitative PCR analysis
Total RNA was isolated using the TRIzol reagent (Life Technologies, Gaithersburg, MD, USA). cDNAs from total RNA of HP, HC1, HC4 and HC8 were synthesized using SuperScript III First-Strand Synthesis System (Invitrogen). Real-time PCR analysis was performed using a Bio-Rad iQ5 Real-Time PCR Detection System (Bio-Rad Laboratories) using the iQ Supermix as recommended by manufacturer. All reactions were performed in triplicate. The sequences of the 
Statistical analysis
Student's t-test was used to evaluate the significance of change in percent growth and EGFR cell surface expression. Statistical analysis to compare tumor sizes in xenograftbearing mice was also done with a t-test. Differences between clones were considered statistically significant if Pp0.05.
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